Abbonarsi

Cohort-driven variant burden analysis and pathogenicity identification in monogenic autoinflammatory disorders - 03/08/23

Doi : 10.1016/j.jaci.2023.03.028 
Xiang Chen, PhD a, Xiaomin Yu, PhD a, b,
a Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China 
b Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China 

Corresponding author: Xiaomin Yu, PhD, Zhejiang University, Yuhangtang Road No. 866, Hangzhou, Zhejiang, China.Zhejiang UniversityYuhangtang Road No. 866HangzhouZhejiangChina

Abstract

Background

Nearly 50 pathogenic genes and hundreds of pathogenic variants have been identified in monogenic autoinflammatory diseases (AIDs). Nonetheless, there are still many genes for which the pathogenic mechanisms are poorly understood, and the pathogenicity of many candidate variants needs to be determined.

Objective

Monogenic AIDs are a group of rare genetic diseases characterized by inflammation as the phenotype. With the development of next-generation sequencing, pathogenic genes have been widely reported and used for clinical screening and diagnosis. The International Society for Systemic Autoinflammatory Diseases has recognized approximately 50 pathogenic genes and hundreds of related pathogenic variants in monogenic AIDs. We plan to investigate these pathogenic variants by conducting a variant burden analysis to determine whether or not there are consistent characteristics.

Methods

We performed a variant burden analysis on the Genome Aggregation Database cohort using the currently reported genetic variants in monogenic AIDs, analyzing the enrichment of allelic signatures and deleterious predictions at the variants. Allelic signatures were extracted from Genome Aggregation Database, and the deleterious predictions were extracted from existing tools. The features obtained from the variant burden analysis were applied to the Random Forest model to classify the pathogenicity of novel mutations.

Results

Functional enrichment and network analysis of AID pathogenic genes have hinted at the possible involvement of unsuspected signals. The variant burden analysis demonstrated that the pathogenicity of a variant could not be reliably classified using only its allele frequency and deleterious predictions. However, variants of varying classifications of pathogenicity exhibited strikingly different patterns of the allelic signature in the upstream and downstream regions surrounding the variants. Furthermore, the distribution of deleterious variants surrounding the variants in the cohort varied significantly across pathogenicity categories. Finally, the cohort-based features extracted from the alleles were applied to the prediction of pathogenicity in monogenic AIDs, achieving superior prediction performance compared with other tools. The cohort-based features have potential applications across a more extensive variety of disease categories.

Conclusions

The pathogenicity of a variant can be effectively classified on the basis of variant frequency and deleterious prediction of the allele in the cohort, and this information can be used to improve the accuracy of the current classification of the pathogenicity of the variant.

Il testo completo di questo articolo è disponibile in PDF.

Key words : Autoinflammatory disease (AIDs), cohort-based features, pathogenic variants, pathogenicity, variant burden analysis

Abbreviations used : AID, gnomAD, GOF, LOF, RCM, VUS


Mappa


 Supported by the Hundred-Talent Program of Zhejiang University.
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2023  American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 152 - N° 2

P. 517-527 - agosto 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Autoimmunity and immunodeficiency associated with monoallelic LIG4 mutations via haploinsufficiency
  • Annaïse J. Jauch, Olivier Bignucolo, Sayuri Seki, Marie Ghraichy, Ottavia M. Delmonte, Valentin von Niederhäusern, Rebecca Higgins, Adhideb Ghosh, Masako Nishizawa, Mariko Tanaka, Adrian Baldrich, Julius Köppen, Julia R. Hirsiger, Robin Hupfer, Stephan Ehl, Anne Rensing-Ehl, Helmut Hopfer, Spasenija Savic Prince, Stephen R. Daley, Florian A. Marquardsen, Benedikt J. Meyer, Michael Tamm, Thomas D. Daikeler, Tamara Diesch, Thomas Kühne, Arthur Helbling, Caroline Berkemeier, Ingmar Heijnen, Alexander A. Navarini, Johannes Trück, Jean-Pierre de Villartay, Annette Oxenius, Christoph T. Berger, Christoph Hess, Luigi D. Notarangelo, Hiroyuki Yamamoto, Mike Recher
| Articolo seguente Articolo seguente
  • The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease
  • Bas Smits, Sigune Goldacker, Suranjith Seneviratne, Marion Malphettes, Hilary Longhurst, Omar E. Mohamed, Carla Witt-Rautenberg, Lucy Leeman, Eva Schwaneck, Isabelle Raymond, Kilifa Meghit, Annette Uhlmann, Christine Winterhalter, Joris van Montfrans, Marion Klima, Sarita Workman, Claire Fieschi, Lorena Lorenzo, Sonja Boyle, Shamin Onyango-Odera, Suzanne Price, Marc Schmalzing, Valerie Aurillac, Antje Prasse, Ieneke Hartmann, Jennifer J. Meerburg, Mariette Kemner-van de Corput, Harm Tiddens, Bodo Grimbacher, Peter Kelleher, Smita Y. Patel, Anne-Sophie Korganow, Jean-Francois Viallard, Hans-Peter Tony, Claire Bethune, Hendrik Schulze-Koops, Torsten Witte, Aarnoud Huissoon, Helen Baxendale, Sofia Grigoriadou, Eric Oksenhendler, Siobhan O. Burns, Klaus Warnatz

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.